New drug combo shows promise for Tough-to-Treat leukemia
NCT ID NCT02632708
First seen May 24, 2026 · Last updated Jun 13, 2026 · Updated 5 times
Summary
This early-stage study is testing the safety of two experimental drugs, AG-120 and AG-221, when given together with standard chemotherapy for adults with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (IDH1 or IDH2 mutation). The study involves about 153 participants and will also look at the best dose to use. After initial treatment, some participants may continue taking the study drug alone to help keep the leukemia under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02114, United States
-
Erasmus MC
Rotterdam, 3075 EA, Netherlands
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Johns Hopkins University
Baltimore, Maryland, 21231, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina - PPDS
Charleston, South Carolina, 29425-0001, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
UCLA Medical Center
Los Angeles, California, 90024, United States
-
Universitatsklinikum Ulm
Ulm, 89081, Germany
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.